Affordable Access

Access to the full text

The Fanconi Anemia Pathway in Cancer

Authors
  • Niraj, Joshi
  • Färkkilä, Anniina
  • D'Andrea, Alan D.
Type
Published Article
Journal
Annual Review of Cancer Biology
Publisher
Annual Reviews
Publication Date
Mar 04, 2019
Volume
3
Pages
457–478
Identifiers
DOI: 10.1146/annurev-cancerbio-030617-050422
Source
Annual Reviews
Keywords
License
Yellow

Abstract

Fanconi anemia (FA) is a complex genetic disorder characterized by bone marrow failure (BMF), congenital defects, inability to repair DNA interstrand cross-links (ICLs), and cancer predisposition. FA presents two seemingly opposite characteristics: (a) massive cell death of the hematopoietic stem and progenitor cell (HSPC) compartment due to extensive genomic instability, leading to BMF, and (b) uncontrolled cell proliferation leading to FA-associated malignancies. The canonical function of the FA proteins is to collaborate with several other DNA repair proteins to eliminate clastogenic (chromosome-breaking) effects of DNA ICLs. Recent discoveries reveal that the FA pathway functions in a critical tumor-suppressor network to preserve genomic integrity by stabilizing replication forks, mitigating replication stress, and regulating cytokinesis. Homozygous germline mutations (biallelic) in 22 FANC genes cause FA, whereas heterozygous germline mutations in some of the FANC genes (monoallelic), such as BRCA1 and BRCA2, do not cause FA but significantly increase cancer susceptibility sporadically in the general population. In this review, we discuss our current understanding of the functions of the FA pathway in the maintenance of genomic stability, and we present an overview of the prevalence and clinical relevance of somatic mutations in FA genes.

Report this publication

Statistics

Seen <100 times